Teva Pharmaceutical Industries (TEVA) US affiliate Teva Pharmaceuticals said Friday that TEV-'749 showed significant improvement in social functioning and quality of life at week eight in adult patients with schizophrenia.
The data is from the acute treatment portion of the phase 3 clinical subcutaneous olanzapine extended-release injection study, according to the company.
The company said no new safety signals for drug delivery method were identified and no post-injection delirium/sedation syndrome events were reported.
Interim results for a phase 1 trial show that the drug delivery method may help prevent the development of post-injection delirium/sedation syndrome, Teva added.
Price: 18.49, Change: +0.05, Percent Change: +0.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.